Product Description
Garetosmab is a VelocImmune-derived fully-human monoclonal antibody that binds and neutralizes Activin A, which is involved in the development of heterotopic bone in people with FOP. Garetosmab is currently being studied in adults with FOP. (Sourced from: https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-encouraging-garetosmab-phase-2-results#:~:text=Garetosmab%20is%20a%20VelocImmune%2Dderived,studied%20in%20adults%20with%20FOP.)
Mechanisms of Action: TGFb Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Brazil, Canada, Chile, China, Colombia, Finland, France, Hong Kong, Italy, Japan, Korea, Malaysia, Netherlands, Poland, Puerto Rico, South Africa, Spain, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Fibrodysplasia Ossificans Progressiva|Myositis Ossificans
Phase 2: Obesity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| R2477-FOP-2175 | P3 |
Unknown Status |
Fibrodysplasia Ossificans Progressiva |
2026-09-29 |
|
| OPTIMA | P3 |
Active, not recruiting |
Fibrodysplasia Ossificans Progressiva |
2026-04-26 |
|
| jRCT2041220096 | P3 |
Recruiting |
Fibrodysplasia Ossificans Progressiva |
2026-03-31 |
|
| COURAGE | P2 |
Recruiting |
Obesity |
2026-02-16 |